For media enquiries or more information about research at the Djavad Mowafaghian Centre for Brain Health, please contact Emily Wight, Communications Manager.

To keep in touch with the Centre and up-to-date on our research, follow us on Twitter or subscribe to Brain Matters, our monthly e-newsletter.

Hopeful mature couple.
Increases in cholinergic system activity affect those with Parkinson-linked gene mutation Feb 16, 2018

A particular gene mutation associated with an inherited form of Parkinson’s disease (PD) offers new clues that call into question a controversial theory that changes associated with PD may begin in a different area of the brain. Idiopathic PD, a spontaneous form of the disease, affects the dopamine system and is treated with replacement therapy to restore the brain’s chemical balance and alleviate physical symptoms. Other neurotransmitter systems are often involved, but it is not clear whether this occurs prior to or after the dopamine loss characteristic of PD.  

Dr. Carles Vilarino-Guell
New MS model provides hope for better understanding of disease pathology Feb 14, 2018

Until now, researchers studying multiple sclerosis (MS) in mouse models have relied on models heavily weighted towards processes secondary to an autoimmune trigger. While discoveries made through these models have informed later translational research and clinical trials to improve drug treatment for people living with MS, a lack of a model for the unique biological process by which the disease progresses in the brain has been challenging.

Teenage girls in a research lab.
MS researcher-led event encourages teenagers to choose science Feb 13, 2018

In Grade 10, fifteen- and sixteen-year-olds begin making the academic decisions that may shape their lives, opting for electives in the sciences or the arts. What they choose will influence where they plan to go to university, what they plan to study, and who they ultimately become.

Helen Tremlett receives substantial CIHR funding to study MS drugs.
A million-dollar study to evaluate MS drug safety and effectiveness Feb 5, 2018

There are more than ten different drug therapies approved in Canada to treat multiple sclerosis (MS), but what do we know about their long-term value? With a $1.2 million endorsement from CIHR, Dr. Helen Tremlett, Canada Research Chair in Neuroepidemiology and Multiple Sclerosis and her team, will determine the safety and effectiveness of commonly prescribed MS drugs.

Dr. Jehannine Austin
Member news: January 2018 Jan 30, 2018


Dr. Judy Illes, Dr. Janet Werker, and Dr. Anne Martin-Matthews have been appointed to the Order of Canada.

Dr. Snutch shows UBC President Santa Ono the MinION sequencing tool.
Longer, better, faster … smaller? New genome sequencing tool promises richer biological insight Jan 29, 2018

For the past three years, Dr. Terrance Snutch and research associate Dr. John Tyson have been working with Oxford Nanopore Technologies (ONT) to develop a novel deoxyribonucleic acid (DNA) sequencing tool with promising implications for personalized medicine. 

 Dr. Zouwei Wang, Dr. Raymond Lam, and Dr. Jun Chen at the Mental Health Centre of Hongkou District, Shanghai
APEC Digital Hub for Mental Health to bring eHealth collaboration to China Jan 28, 2018

Pictured, left to right: Dr. Zouwei Wang, Dr. Raymond Lam, and Dr. Jun Chen at the Mental Health Centre of Hongkou District, Shanghai

Significant brain research funding for DMCBH member projects Jan 24, 2018

With several major funding announcements made across Canada this week, we're excited to congratulate our members on securing funding for important research projects. 

Teenage soccer player on field.
Concussion stalls adolescent brains, reduces cognitive flexibility Jan 23, 2018

New research from Dr. Naznin Virji-Babul’s team shows that concussion changes the way that different neural networks interact, stalling the brain in a state of cognitive inflexibility.

Nurse in hospital
Comorbidities affect MS relapse risk and disability progression Jan 8, 2018

For people with multiple sclerosis (MS), the presence of comorbidities—chronic conditions in addition to the primary diagnosis of MS—can affect the risk of relapse and disability progression. Two new papers involving Dr. Helen Tremlett’s team look at comorbidities from two distinct angles, providing new insight into how people living with MS are affected by additional chronic conditions.